 Cytarabine
"Cytarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
| Descriptor ID |
D003561
|
| MeSH Number(s) |
D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453
|
| Concept/Terms |
Cytarabine- Cytarabine
- Arabinosylcytosine
- Cytosine Arabinoside
- Arabinoside, Cytosine
- Arabinofuranosylcytosine
- Aracytidine
Cytosar- Cytosar
- Cytosar-U
- Cytosar U
- CytosarU
|
Below are MeSH descriptors whose meaning is more general than "Cytarabine".
Below are MeSH descriptors whose meaning is more specific than "Cytarabine".
This graph shows the total number of publications written about "Cytarabine" by people in this website by year, and whether "Cytarabine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 3 | 3 | | 1982 | 0 | 2 | 2 | | 1984 | 1 | 3 | 4 | | 1985 | 3 | 4 | 7 | | 1986 | 2 | 0 | 2 | | 1987 | 1 | 1 | 2 | | 1988 | 1 | 2 | 3 | | 1989 | 1 | 0 | 1 | | 1990 | 0 | 2 | 2 | | 1991 | 2 | 3 | 5 | | 1992 | 3 | 1 | 4 | | 1993 | 2 | 2 | 4 | | 1995 | 0 | 2 | 2 | | 1996 | 1 | 1 | 2 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 4 | 4 | | 2002 | 0 | 4 | 4 | | 2003 | 2 | 5 | 7 | | 2004 | 4 | 5 | 9 | | 2005 | 0 | 1 | 1 | | 2006 | 2 | 2 | 4 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 4 | 6 | | 2009 | 2 | 2 | 4 | | 2010 | 0 | 7 | 7 | | 2011 | 0 | 4 | 4 | | 2012 | 2 | 4 | 6 | | 2013 | 2 | 4 | 6 | | 2014 | 0 | 3 | 3 | | 2015 | 1 | 1 | 2 | | 2017 | 0 | 2 | 2 | | 2018 | 1 | 1 | 2 | | 2019 | 2 | 2 | 4 | | 2020 | 1 | 4 | 5 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytarabine" by people in Profiles.
-
Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mrózek K, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787.
-
Arber DA, Erba HP. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
-
Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.
-
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
-
Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
-
Marcucci G, Geyer S, Laumann K, Zhao W, Bucci D, Uy GL, Blum W, Eisfeld AK, Pardee TS, Wang ES, Stock W, Kolitz JE, Kohlschmidt J, Mrózek K, Bloomfield CD, Stone RM, Larson RA. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020 02 25; 4(4):696-705.
-
Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020 08; 105(8):e404-e407.
-
Derman BA, Larson RA. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? Best Pract Res Clin Haematol. 2019 12; 32(4):101102.
-
Dama P, Tang M, Fulton N, Kline J, Liu H. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019 07 10; 7(1):175.
-
Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|